1-20 of 28213 Search Results for

drug-combination

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3095.
Published: 15 June 2022
.... Methods: Considering previously published criteria for selecting drug combinations for overcoming drug resistances1, we have established a low dose combination therapy with cabozantinib, afatinib, etoricoxib and plerixafor. Utilizing NSCLC patient-derived xenograft (PDX) models we aimed to use...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1048.
Published: 15 June 2022
... therapeutic response to SP-2577 may be obtained by combining drugs that target multiple pathways and/or inhibit resistance mechanisms. Experimental Design: In this study, we applied an arrayed CRISPR screening (Synthego) to identify survival genes that can be candidates for molecularly targeted drugs. Gene...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1907.
Published: 15 June 2022
...William C. Wright; Min Pan; Hyeong-Min Lee; Gregory A. Phelps; Jonathan Low; Duane Currier; Richard E. Lee; Taosheng Chen; Paul Geeleher Drug combinations are the basis of treatment for modern diseases but arriving at successful combination therapies is fraught with challenges. Decades ago...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 96.
Published: 15 June 2022
... by which triptolide enhances MV oncolysis and will be presented at the meeting. Citation Format: Valery A. Chavez, Floritza Bustamante, Abner Murray, Ashok Saluja, Jaime Merchan. A novel virus-drug combination to enhance oncolysis in colorectal cancer (crc) [abstract]. In: Proceedings of the American...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1881.
Published: 15 June 2022
...Thomas Steven Dexheimer; Thomas Silvers; Rene Delosh; Julie Laudeman; Russell Reinhart; Chad Ogle; Siddhartha Paul; Nathan P. Coussens; Ralph E. Parchment; Joel Morris; John Wright; Naoko Takebe; Beverly A. Teicher; James H. Doroshow Drug combinations are frequently used to improve clinical...
Journal Articles
Cancer Res (2022) 82 (10_Supplement): A034.
Published: 15 May 2022
...Ying Yuan; Suyu Liu Drug combination therapy is the most commonly used approach to overcome acquired resistance to cancer therapy. Designing phase I drug combination trials faces several challenges beyond the conventional single-agent dose escalation studies, e.g., two-dimensional dose space...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT216.
Published: 15 June 2022
.... CIVO (Comparative In Vivo Oncology) is an intratumoral microdose injection research tool intended to bridge the translational gap between preclinical and clinical studies by enabling in situ assessment of up to 8 oncology drugs or drug combinations simultaneously within a patient’s tumor. The CIVO...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3424.
Published: 15 June 2022
... demonstrated significant clinical improvement over CPI alone. This indicates a need for approaches that can guide development of complex (≥ 3 drug) I-O combination treatments by enabling far greater mechanistic understanding of response to drug exposure by components of the authentic tumor microenvironment...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1002.
Published: 15 June 2022
... survival programs and compensate for the therapeutic impact. Oncogenic dependencies to such adaptive events, however, can generate new therapeutic vulnerabilities that can be targeted with drug combinations. The precision medicine approaches in which targeted drugs are matched to pre-existing genomic...
Journal Articles
Cancer Res (2022) 82 (10_Supplement): B026.
Published: 15 May 2022
...Elysia Saputra; Lisa Tucker-Kellogg Cancer therapies often have short duration of success due to the development of drug-resistance, which motivates research into anti-evolutionary therapies. A popular strategy is to combine two drugs, particularly if they have synergistic (greater-than-additive...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4056.
Published: 15 June 2022
... treated with the novel triple drug combination ONC201, etoposide, and carboplatin. Cell-Titer Glo cell viability assays were conducted for 72 hours to see the additive and/or synergistic effect of novel triple drug treatment. Western blots were also run to evaluate the expression of proapoptotic protein...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2739.
Published: 15 June 2022
...Haeun Hwangbo; Adam C. Palmer BACKGROUND The benefits of combination therapy are often attributed to synergy, that is, drug interactions resulting in an anti-cancer effect that is more than the sum of its parts. Accordingly, the rationale for designing new drug combinations is often based...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 200.
Published: 15 June 2022
... in several Cancers-Lung, Breast and Colon cancers; with unprecedented flexibility of being screened against multiple drug class (including anti-PD1/PDL1) in monotherapy and combination therapy settings. Despite being a phenotypic based assay, the test cycle of MTAM-HFA is only 7-10 days while maintaining...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5399.
Published: 15 June 2022
... effects when combined with doxorubicin (DOX) and co-loaded in an integrin-targeted iRGD-modified nanoparticle system (iRGD-DOX-oHA-PLNs). This study aims to investigate the inhibitory effect of iRGD-DOX-oHA-PLNs on both DNA single-strand break (SSB) and double-strand break (DSB) repair proteins and drug...
Journal Articles
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1079.
Published: 15 June 2022
..., Alain Larocque, Alain Zgheib, Richard Béliveau, Borhane Annabi. Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin [abstract]. In: Proceedings of the American Association for Cancer...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1794.
Published: 15 June 2022
..., Cathy Lan, Josiane Lafleur, Cedric Darini, Urszula Krzemien, Adriana Aguilar-Mahecha, Mark Basik. The combination of Talazoparib with anti-her2 drugs shows efficacy in drug resistant Her2+ and low Her2 PDX models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4196.
Published: 15 June 2022
... intratumor drug responses and anti-tumor immunity for eleven agents in parallel. Local tumor response is measured by cyclical immunofluorescence for deep cellular response phenotyping. This approach is combined with the systemic administration of checkpoint inhibitors to examine whether local immunogenic...
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 1054.
Published: 01 July 2021
.... New therapies that work via immune and BRAF-independent mechanisms are urgently required for tumors that are unresponsive to currently available treatments. Here we hypothesized that combination of Aurora Kinase inhibitor (AURKAi) alisertib (senescence inducer) with a drug that selectively kills...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1108.
Published: 15 June 2022
... effectively reduce tumor cell proliferation and growth and improve tumor microenvironment, we treated chemo resistant SCLCs with HeSP2 and in combination with commonly used chemo drugs cisplatin and etoposide. Our data shows that HesP2 can strongly inhibit cell proliferation and decreases oxygen consumption...